T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AIV
626
Aimco
AIV
$378M
| $103M | 0.01% |
17,286,866
-9,500
| -0.1% | -$56.9K |
|
627
Federal Signal
FSS
$7.56B
| $103M | 0.01% |
945,229
+214,319
| +29% | +$24.5M |
|
628
Bloom Energy
BE
$70.9B
| $102M | 0.01% |
1,170,243
-2,201,741
| -65% | -$231M |
|
629
PayPal
PYPL
$51.3B
| $100M | 0.01% |
1,712,253
+28,833
| +2% | +$1.87M |
|
630
Compass
COMP
$10.2B
| $99M | 0.01% |
9,362,368
+8,962,488
| +2,241% | +$81.8M |
|
|
TTAN
631
ServiceTitan Inc
TTAN
$8.68B
| $98.9M | 0.01% |
928,620
-95,353
| -9% | -$9.31M |
|
|
SOMN
632
The Southern Company 2025 Series A Corp Units
SOMN
| – | – |
0
| – | – |
|
|
CNTA
633
DELISTED
Centessa Pharmaceuticals
CNTA
| $98.2M | 0.01% |
3,927,343
-876,713
| -18% | -$22.2M |
|
634
DexCom
DXCM
$34.4B
| $97.5M | 0.01% |
1,468,908
-429,137
| -23% | -$27.7M |
|
635
Huntington Ingalls Industries
HII
$12.8B
| $97M | 0.01% |
285,339
+227,126
| +390% | +$70.5M |
|
636
Coherent
COHR
$65.3B
| $96.7M | 0.01% |
524,175
+41,690
| +9% | +$6.24M |
|
637
Energy Fuels
UUUU
$3.64B
| $96M | 0.01% |
6,604,349
-2,370,744
| -26% | -$40.2M |
|
638
Incyte
INCY
$24.4B
| $95.4M | 0.01% |
965,846
+184,497
| +24% | +$17.9M |
|
639
Apogee Therapeutics
APGE
$10.2B
| $93.4M | 0.01% |
1,237,135
+486,606
| +65% | +$30.6M |
|
640
West Pharmaceutical
WST
$24.5B
| $93.3M | 0.01% |
339,267
+224,722
| +196% | +$61.5M |
|
641
Kimco Realty
KIM
$16.3B
| $93.3M | 0.01% |
4,601,619
-842,159
| -15% | -$17.5M |
|
642
FedEx
FDX
$79.3B
| $92.4M | 0.01% |
320,000
+1,737
| +0.5% | +$456K |
|
643
Flutter Entertainment
FLUT
$16.9B
| $92M | 0.01% |
427,787
-64,052
| -13% | -$14.4M |
|
644
Wayfair
W
$13.9B
| $91.5M | 0.01% |
911,583
+827,470
| +984% | +$79.6M |
|
645
Cboe Global Markets
CBOE
$30.6B
| $91.1M | 0.01% |
362,896
-67,126
| -16% | -$16.7M |
|
646
Cogent Biosciences
COGT
$6.55B
| $91.1M | 0.01% |
2,564,062
+2,474,346
| +2,758% | +$69.6M |
|
647
Tapestry
TPR
$26B
| $91M | 0.01% |
712,605
-439,704
| -38% | -$50.3M |
|
648
Federal Realty Investment Trust
FRT
$10.3B
| $90.9M | 0.01% |
902,209
+23,519
| +3% | +$2.32M |
|
649
Frontdoor
FTDR
$5.87B
| $90.6M | 0.01% |
1,570,668
-246,798
| -14% | -$14.5M |
|
650
Lamar Advertising Co
LAMR
$15.9B
| $90.6M | 0.01% |
715,787
+76,409
| +12% | +$9.56M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.